Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

Inclusion Criteria: * Histological or cytological diagnosis of non-Hodgkin's lymphoma * Disease exclusively localised into the CNS at first diagnosis and failure * Progressive or recurrent disease * Previous treatment with HDMTX containing CHT and/or RT * Presence of at least one target lesion, bidimensionally measurable * Age 18 - 75 years * ECOG performance status \< 3 (Appendix 1). * No known HIV disease or immunodeficiency * HBsAg-negative and Ab anti-HCV-negative patients. * Adequate bone marrow function (plt \> 100000 mm3, Hb \> 9 g/dl, ANC \> 2.000 mm3) * Adequate renal function (serum creatinine \< 2 times UNL) * Adequate hepatic function (SGOT/SGPT \< 3 times UNL, bilirubin and alkaline phosphatase \< 2 times UNL) * Adequate cardiac function (VEF ≥ 50%) * Absence of any psycological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Non-pregnant and non-lactating status for female patients. Adequate contraceptive measures during study participation for sexually active patients of childbearing potential. * No previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease since at least 5 years. * No concurrent treatment with other experimental drugs. * Informed consent signed by the patient before registration